Eli Lilly (LLY) said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's (NVO) Wegovy in the first-ever head-to-head study. XNOW PLAYINGThe Weight-Loss Drug Market Is Ho… [+2914 chars]
EURO 2020 match …
Arrested…
Almost l…
Leave Comments